127 related articles for article (PubMed ID: 34622834)
21. A Randomized Phase 2 Trial of Consolidation Chemotherapy After Preoperative Chemoradiation Therapy Versus Chemoradiation Therapy Alone for Locally Advanced Rectal Cancer: KCSG CO 14-03.
Kim SY; Joo J; Kim TW; Hong YS; Kim JE; Hwang IG; Kim BG; Lee KW; Kim JW; Oh HS; Ahn JB; Zang DY; Kim DY; Oh JH; Baek JY
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):889-899. PubMed ID: 29976501
[TBL] [Abstract][Full Text] [Related]
22. Improved outcomes for rectal cancer in the era of preoperative chemoradiation and tailored mesorectal excision: a series of 338 consecutive cases.
Pacelli F; Sanchez AM; Covino M; Tortorelli AP; Bossola M; Valentini V; Gambacorta MA; Doglietto GB
Am Surg; 2013 Feb; 79(2):151-61. PubMed ID: 23336654
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.
Chau I; Brown G; Cunningham D; Tait D; Wotherspoon A; Norman AR; Tebbutt N; Hill M; Ross PJ; Massey A; Oates J
J Clin Oncol; 2006 Feb; 24(4):668-74. PubMed ID: 16446339
[TBL] [Abstract][Full Text] [Related]
24. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).
Dewdney A; Cunningham D; Tabernero J; Capdevila J; Glimelius B; Cervantes A; Tait D; Brown G; Wotherspoon A; Gonzalez de Castro D; Chua YJ; Wong R; Barbachano Y; Oates J; Chau I
J Clin Oncol; 2012 May; 30(14):1620-7. PubMed ID: 22473163
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of neoadjuvant intensity-modulated radiotherapy with concurrent capecitabine for locally advanced rectal cancer.
Wang L; Li ZY; Li ZW; Li YH; Sun YS; Ji JF; Gu J; Cai Y
Dis Colon Rectum; 2015 Feb; 58(2):186-92. PubMed ID: 25585076
[TBL] [Abstract][Full Text] [Related]
26. Survival Outcomes After Surgical Management of the Primary Tumor With and Without Radiotherapy for Metastatic Rectal Adenocarcinoma: A National Cancer Database (NCDB) Analysis.
Renz P; Wegner RE; Hasan S; Brookover R; Finley G; Monga D; Raj M; McCormick J; Kirichenko A
Clin Colorectal Cancer; 2019 Jun; 18(2):e237-e243. PubMed ID: 30905549
[TBL] [Abstract][Full Text] [Related]
27. Rechallenge capecitabine after fluoropyrimidine-induced cardiotoxicity in rectal cancer: A case report.
Peng T; Ouyang Y; Tong K
Medicine (Baltimore); 2019 Jan; 98(2):e14057. PubMed ID: 30633206
[TBL] [Abstract][Full Text] [Related]
28. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study.
Yu X; Wang QX; Xiao WW; Chang H; Zeng ZF; Lu ZH; Wu XJ; Chen G; Pan ZZ; Wan DS; Ding PR; Gao YH
Cancer Commun (Lond); 2018 May; 38(1):24. PubMed ID: 29784042
[TBL] [Abstract][Full Text] [Related]
30. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial†.
Fernandez-Martos C; Garcia-Albeniz X; Pericay C; Maurel J; Aparicio J; Montagut C; Safont MJ; Salud A; Vera R; Massuti B; Escudero P; Alonso V; Bosch C; Martin M; Minsky BD
Ann Oncol; 2015 Aug; 26(8):1722-8. PubMed ID: 25957330
[TBL] [Abstract][Full Text] [Related]
31. Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study.
Czito BG; Deming DA; Jameson GS; Mulcahy MF; Vaghefi H; Dudley MW; Holen KD; DeLuca A; Mittapalli RK; Munasinghe W; He L; Zalcberg JR; Ngan SY; Komarnitsky P; Michael M
Lancet Gastroenterol Hepatol; 2017 Jun; 2(6):418-426. PubMed ID: 28497757
[TBL] [Abstract][Full Text] [Related]
32. [Long-Term Survival of a Patient with Rectal Neuroendocrine Carcinoma after Treatment with Curative Resection and Adjuvant Chemotherapy with Capecitabine].
Furumoto K; Kogire M; Iizuka N
Gan To Kagaku Ryoho; 2015 Dec; 42(13):2485-8. PubMed ID: 26809310
[TBL] [Abstract][Full Text] [Related]
33. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
34. Capecitabine and Oxaliplatin Before, During, and After Radiotherapy for High-Risk Rectal Cancer.
Larsen FO; Markussen A; Jensen BV; Fromm AL; Vistisen KK; Parner VK; Linnemann D; Hansen RH; Johannesen HH; Schou JV
Clin Colorectal Cancer; 2017 Jun; 16(2):e7-e14. PubMed ID: 27743742
[TBL] [Abstract][Full Text] [Related]
35. Endocrine cell carcinomas of the colon and rectum: a clinicopathological evaluation.
Komatsubara T; Koinuma K; Miyakura Y; Horie H; Morimoto M; Ito H; Lefor AK; Sata N; Fukushima N
Clin J Gastroenterol; 2016 Feb; 9(1):1-6. PubMed ID: 26699873
[TBL] [Abstract][Full Text] [Related]
36. Preoperative capecitabine and accelerated intensity-modulated radiotherapy in locally advanced rectal cancer: a phase II trial.
Ballonoff A; Kavanagh B; McCarter M; Kane M; Pearlman N; Nash R; Shah RJ; Raben D; Schefter TE
Am J Clin Oncol; 2008 Jun; 31(3):264-70. PubMed ID: 18525306
[TBL] [Abstract][Full Text] [Related]
37. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
[No Abstract] [Full Text] [Related]
38. Short-Course Radiotherapy Followed by Neoadjuvant Bevacizumab, Capecitabine, and Oxaliplatin and Subsequent Radical Treatment in Primary Stage IV Rectal Cancer: Long-Term Results of a Phase II Study.
Bisschop C; van Dijk TH; Beukema JC; Jansen RLH; Gelderblom H; de Jong KP; Rutten HJT; van de Velde CJH; Wiggers T; Havenga K; Hospers GAP
Ann Surg Oncol; 2017 Sep; 24(9):2632-2638. PubMed ID: 28560600
[TBL] [Abstract][Full Text] [Related]
39. Comparison of Capecitabine (Xeloda) vs. Combination of Capecitabine and Oxaliplatin (XELOX) as Neoadjuvant CRT for Locally Advanced Rectal Cancer.
Yaghobi Joybari A; Azadeh P; Babaei S; Hosseini Kamal F
Pathol Oncol Res; 2019 Oct; 25(4):1599-1605. PubMed ID: 30712194
[TBL] [Abstract][Full Text] [Related]
40. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]